Avandia Lawsuit News

09/06/2008
The Food and Drug Administration will begin posting every three months a list of drugs whose safety is under investigation because of complaints brought to the agency's attention by drug companies, physicians and patients.

09/03/2008
Avandia has been the subject of widespread speculation that has brought drug manufacturer GlaxoSmithKline under fire for product liability claims. The drug, used to treat Type 2 diabetes, has been linked to cardiovascular deaths and serious health conditions.

09/02/2008
According to researchers at Wake Forest University, a class of oral drugs (the thiazolidinediones), which includes Avandia (rosiglitazone) and Actos (pioglitazone) may make heart failure worse in people with type 2 diabetes.

08/30/2008
Marina Del Ray, CA: Marla's mother, Vivian, died of heart failure less than a month after starting on Avandia. While Vivian was diabetic, Marla had no indication that her mother could suddenly die of heart failure. But now she wonders if Avandia played a role in her mother's death.

More Avandia News:::

Avandia Side Effects Lawsuit
NO RECOVERY... NO FEES...NO COSTS

Avandia - Rosiglitazone is a widely prescribed medication to treat Type-2 Diabetes Mellitus, a condition which also known as Adult-Onset Diabetes. Manufactured by GlaxoSmithKline, Avandia (Rosiglitazone) was approved for the treatment of Type-2 Diabetes in the U.S. in 1999. Avandia is also contained in combination with other drugs in medications called Avandryl and Avandamet. To date, more than six (6) million people worldwide have taken the drug, and Avandia generates approximately $3.2 billion in annual sales for its manufacturer. However, on May 21, 2007, the United States Food & Drug Administration ("FDA") issued a Safety Alert regarding Avandia. To date there has not yet been a recall or a black box warning required by the FDA for Avandia.

The FDA Safety Alert warns that patients who are taking Avandia (rosiglitazone) - especially those who are known to have underlying heart disease or who are at high risk of heart attack (myocardial infarction) -  should speak to their physicians about their continued use of Avandia.

The FDA's Safety Alert follows a study released on the same day, which will appear in the June 14, 2007 issue of the New England Journal of Medicine. This type of study, known as a 'meta-analysis', evaluated forty-two (42) separate studies comparing patients using Avandia (rosiglitazone) to patients who were not using Avandia. This study concludes that patients taking Avandia (rosiglitazone) face a 43% increased risk of heart attack, and a 64% increased risk of dying from heart related ( cardiovascular) disease. Cardiovascular disease refers to the class of diseases that affect the heart and/or blood vessels, which includes but is not limited to heart attacks (myocardial infarction), strokes, aneurysms, congestive heart failure, and arrhythmia. As indicated above, there has not yet been a recall, nor has the FDA yet required that the manufacturer issue a black box warning label for Avandia, but in the event Avandia is subjected to a recall, this site will be updated.

ALERT - On June 7, 2007 the FDA ordered an Avandia Black Box Warning.

If you or a loved one have experienced an Avandia heart attack, or Avandia stroke, Avandia congestive heart failure, Avandia cardiovascular disease or if you have lost a loved one to an Avandia death you may be entitled to compensation. Contact the Avandia lawyers of Ennis & Ennis, P.A. today about an Avandia lawsuit. Call us toll free for a free, confidential case evaluation or fill out our online Avandia case evaluation form on this page.